Cytogenix (fka CYGX)

[Jimmy Joe]

Note the contacts in this PR please!

CytoGenix Receives Re-Supply Order for synDNA(TM)
Tuesday June 13, 9:15 am ET


HOUSTON--(BUSINESS WIRE)--June 13, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced a follow-on order for the production of synDNA(TM) from a client referred by Aldevron, LLC (Fargo, ND).
ADVERTISEMENT


The current order for synDNA(TM) was placed after the initial batch of synDNA(TM) proved to be the preferred material for use in the manufacture of innovative products by the client. While the details of the order were not disclosed, success in the next, final series of tests could result in future orders for gram quantities of custom synDNA(TM) material to satisfy the client's anticipated demand.

"The CytoGenix synDNA(TM) technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron. "The first order of synDNA(TM) met and exceeded our expectations in terms of quality, cost, and turn-around time."

"The relationship between CytoGenix and Aldevron continues to be mutually beneficial," said Malcolm Skolnick, President and CEO of CytoGenix. "We are delighted to service clients by utilizing our excess production capacity thereby generating revenue to fund our internal product development programs."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.

About Aldevron: Aldevron provides contract services to accelerate gene and protein based research. These include plasmid and protein manufacturing for preclinical and clinical applications. For instance, Aldevron manufactures a west-Nile vaccine that has been recognized as the world's first DNA vaccine to be used outside of a trial setting. Aldevron's GIA(TM) technology can be used to rapidly screen new vaccines and to develop antibodies to any gene-specific antigens. Aldevron has facilities in Fargo, ND and Freiburg, Germany. For more information, please visit http://www.aldevron.com

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.



Contact:
CytoGenix, Inc.
Kurt L. Berens, 713-789-0070
or
Aldevron, LLC
Michael Chambers, 701-297-9256